Patents by Inventor Laykea Tafesse

Laykea Tafesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200361936
    Abstract: The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The application is also directed to compounds of formulae II, I-a, I-a1, I-a2, I-b, and I-b1 and the pharmaceutically acceptable salts, radiolabeled isomers, solvates, and hydrates thereof. The application is also directed to use of Compounds of the present disclosure to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain Compounds of the present disclosure are especially useful for treating pain. In one embodiment, Compounds of the present disclosure exhibit less opioid-induced side effects (such as, euphoria or drug-liking).
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventor: Laykea Tafesse
  • Publication number: 20200361929
    Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 19, 2020
    Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
  • Patent number: 10774050
    Abstract: The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 15, 2020
    Assignee: Purdue Pharma, L.P.
    Inventors: Chiyou Ni, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman, Minnie Park, Bin Shao
  • Patent number: 10745402
    Abstract: The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The application is also directed to compounds of formulae II, I-a, I-a1, I-a2, I-b, and I-b1 and the pharmaceutically acceptable salts, radiolabeled isomers, solvates, and hydrates thereof. The application is also directed to use of Compounds of the present disclosure to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain Compounds of the present disclosure are especially useful for treating pain. In one embodiment, Compounds of the present disclosure exhibit less opioid-induced side effects (such as, euphoria or drug-liking).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Patent number: 10738026
    Abstract: The Invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, or diastereomers thereof: wherein W1, W2, W3, J1, J2, A, R1, R2, R3, R4, R5, a, and b are defined as set forth in the specification. The Invention also provides uses of the compounds of any one of Formulae (I)-(VIII) and the pharmaceutically acceptable salts, solvates, hydrates, N-oxides, or diastereomers thereof. Compounds of the Invention are useful for treating a disorder responsive to blockade of one or more sodium channels. In certain embodiments, Compounds of the Invention are useful for treating pain.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: August 11, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Laykea Tafesse, Jae Hyun Park
  • Patent number: 10730866
    Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: August 4, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
  • Publication number: 20200239460
    Abstract: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: July 30, 2020
    Inventors: Shigeru Ando, Noriyuki Kurose, Laykea Tafesse
  • Publication number: 20200148646
    Abstract: The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R?, R?, R?? R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I or II and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors. Certain compounds of the invention are especially useful for treating pain.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jae Hyun Park, Mark A. Youngman
  • Patent number: 10584110
    Abstract: The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: March 10, 2020
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Patent number: 10550090
    Abstract: The disclosure provides processes of preparing compounds of Formula (I) and Formula (IV), their salts, and intermediates thereof, wherein R1, R2, R3, and R7 are defined as set forth in the specification.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: February 4, 2020
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Patent number: 10550088
    Abstract: The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R?, R?, R?? R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I or II and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors. Certain compounds of the invention are especially useful for treating pain.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: February 4, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jae Hyun Park, Mark A. Youngman
  • Publication number: 20190330208
    Abstract: The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The application is also directed to compounds of formulae II, I-a, I-a1, I-a2, I-b, and I-b1 and the pharmaceutically acceptable salts, radiolabeled isomers, solvates, and hydrates thereof. The application is also directed to use of Compounds of the present disclosure to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain Compounds of the present disclosure are especially useful for treating pain. In one embodiment, Compounds of the present disclosure exhibit less opioid-induced side effects (such as, euphoria or drug-liking).
    Type: Application
    Filed: December 20, 2017
    Publication date: October 31, 2019
    Inventor: Laykea Tafesse
  • Patent number: 10450308
    Abstract: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 22, 2019
    Assignees: Purdue Pharma L.P., Shionogi & Co. Ltd.
    Inventors: Shigeru Ando, Noriyuki Kurose, Laykea Tafesse
  • Patent number: 10435406
    Abstract: The application provides compounds of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, dash line a, dash line b, W, Z, X, and m are defined as set forth in the specification. The invention is also directed to use of the compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. In certain embodiments, the Compounds of the Invention are useful for treating pain.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 8, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Andrew Kassick, Dawit Tadesse, Laykea Tafesse
  • Publication number: 20190292149
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: January 23, 2019
    Publication date: September 26, 2019
    Inventors: Donald James Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Publication number: 20190201410
    Abstract: This application relates to using trace amine associated receptor 1 (TAAR1) agonists and/or partial agonists for treating or preventing pain, especially neuropathic pain.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 4, 2019
    Applicant: Purdue Pharma L.P.
    Inventors: Michele HUMMEL, Donald J. KYLE, Laykea TAFESSE, Garth WHITESIDE
  • Publication number: 20190144400
    Abstract: The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 16, 2019
    Applicant: PURDUE PHARMA L.P.
    Inventors: Paul BLAKE, Laykea TAFESSE
  • Publication number: 20190084942
    Abstract: The disclosure provides processes of preparing compounds of Formula (I) and Formula (IV), their salts, and intermediates thereof, wherein R1? R2? R3, and R7 are defined as set forth in the specification.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 21, 2019
    Inventor: Laykea Tafesse
  • Patent number: 10202344
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 12, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Patent number: 10202382
    Abstract: The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, Y, and Z are defined as set forth in the specification. The invention is also directed to use of compounds of any one of Formulae I-VIII, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the invention are especially useful for treating pain.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 12, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Jae Hyun Park, Laykea Tafesse